Hikma Pharmaceuticals Quality Score

Hikma Pharmaceuticals scores 39 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a 18.9% operating margin and a 12.7% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from HIK.XLON's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Hikma Pharmaceuticals scores well and where it falls behind.

Hikma Pharmaceuticals earns about 12.7% on its invested capital, which is solid. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to HIK.XLON's margins and growth on this scorecard to judge durability.

Hikma Pharmaceuticals runs an operating margin of about 18.9% and a net margin of about 12.2%. Revenue has grown at roughly 7.0% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.